Association of a Phosphorus Counting Table with Sevelamer for control of blood level of phosphorus in hemodialysis patients

Not Applicable

• Conditions: Hyperphosphatemia; renal dialysis; chronicKidney disease-mineral and bone disorder; C18.452.750.199; E02.870.300; C05.116.198.816.750

• Registration Number: RBR-94dhdy
• Lead Sponsor: Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-05-31
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients on hemodialysis for at least 6 months and who underwent a dialysis regimen at three times a week with a duration of four hours per session; age range greater than or equal to 18 years; literate or had literate carer; phosphate binder use for at least 12 weeks; parathyroid hormone less than 800pg/mL; signed the written informed consent form

Exclusion Criteria

Patients who missed more than one hemodialysis session per month; patients in use of anti-inflammatory hormones; patients with neoplasias or active infectious diseases; patients with indication of use of calcium carbonate as phosphate binder and who had no indication of sevelamer hydrochloride use; hypophosphatemic patients

Study & Design

• Study Type: Intervention
• Study Design: Not specified